Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1980 1
1981 1
1983 1
1985 1
1987 2
1988 2
1990 2
1993 2
1994 1
1995 1
1996 2
1999 1
2000 1
2001 1
2002 1
2005 2
2007 1
2008 1
2010 4
2011 1
2012 2
2013 4
2014 1
2015 1
2016 3
2017 4
2018 5
2019 4
2020 5
2021 4
2022 3
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

62 results
Results by year
Filters applied: . Clear all
Page 1
LSD1 inhibition: a therapeutic strategy in cancer?
Lynch JT, Harris WJ, Somervaille TC. Lynch JT, et al. Expert Opin Ther Targets. 2012 Dec;16(12):1239-49. doi: 10.1517/14728222.2012.722206. Epub 2012 Sep 8. Expert Opin Ther Targets. 2012. PMID: 22957941 Review.
LSD1 inhibitors disrupt the GFI1 transcription repressor complex.
Maiques-Diaz A, Lynch JT, Spencer GJ, Somervaille TCP. Maiques-Diaz A, et al. Among authors: lynch jt. Mol Cell Oncol. 2018 Aug 1;5(4):e1481813. doi: 10.1080/23723556.2018.1481813. eCollection 2018. Mol Cell Oncol. 2018. PMID: 30250927 Free PMC article.
Large Independent Primary Care Medical Groups.
Casalino LP, Chen MA, Staub CT, Press MJ, Mendelsohn JL, Lynch JT, Miranda Y. Casalino LP, et al. Among authors: lynch jt. Ann Fam Med. 2016 Jan-Feb;14(1):16-25. doi: 10.1370/afm.1890. Ann Fam Med. 2016. PMID: 26755779 Free PMC article.
Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft Model.
De Fusco C, Schimpl M, Börjesson U, Cheung T, Collie I, Evans L, Narasimhan P, Stubbs C, Vazquez-Chantada M, Wagner DJ, Grondine M, Sanders MG, Tentarelli S, Underwood E, Argyrou A, Smith JM, Lynch JT, Chiarparin E, Robb G, Bagal SK, Scott JS. De Fusco C, et al. Among authors: lynch jt. J Med Chem. 2021 May 27;64(10):6814-6826. doi: 10.1021/acs.jmedchem.1c00067. Epub 2021 Apr 26. J Med Chem. 2021. PMID: 33900758 Free article.
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, Cureton N, Staniszewska A, McEwen R, Fox M, Pilling J, Hopcroft P, Coker EA, Jaaks P, Garnett MJ, Isherwood B, Serra V, Davies BR, Barry ST, Lynch JT, Yusa K. Dunn S, et al. Among authors: lynch jt. Oncogene. 2022 Nov;41(46):5046-5060. doi: 10.1038/s41388-022-02482-9. Epub 2022 Oct 14. Oncogene. 2022. PMID: 36241868 Free PMC article.
Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens.
Gonçalves E, Segura-Cabrera A, Pacini C, Picco G, Behan FM, Jaaks P, Coker EA, van der Meer D, Barthorpe A, Lightfoot H, Mironenko T, Beck A, Richardson L, Yang W, Lleshi E, Hall J, Tolley C, Hall C, Mali I, Thomas F, Morris J, Leach AR, Lynch JT, Sidders B, Crafter C, Iorio F, Fawell S, Garnett MJ. Gonçalves E, et al. Among authors: lynch jt. Mol Syst Biol. 2020 Jul;16(7):e9405. doi: 10.15252/msb.20199405. Mol Syst Biol. 2020. PMID: 32627965 Free PMC article.
62 results